India's IPCA buys plant as it deals with FDA issues

Indian drugmaker IPCA, which has stopped shipping products to the U.S. and Canada from a plant in Bangalore, has acquired a high potency oral solid dosage facility from Alpa Laboratories. It paid about $12 million for the unit in Pithampur, Indore, VCCircle reports. The FDA in July put an import alert on products coming from IPCA's Bangalore plant after an FDA inspection turned up questions about data integrity there. Canadian regulators, working off of FDA info, have since banned 20 APIs and 50 products. Story | More